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Patients (or Materials) and Methods: New insulin analogue AKR 
of a potential long-acting feature was evaluated in the Institute of 
Biotechnology and Antibiotics. Bioactivity of AKR was compared 
with that of USP human insulin standard in bioassays on cells and 
rabbits, while the pharmacodynamic activity on rats was referred to 
control group received 0.9% NaCl. The 3T3-L1 cells differentiated 
into adipocytes were used for the performance of insulin dependent 
glucose uptake experiment. Dose-response relationship of log insu-
lin concentration and Deoxy-D-glucose uptake of AKR was deter-
mined. The biological activity on animals was assessed on 24 albino 
rabbits according to US Pharmacopeia. The glucose concentrations 
were measured with spectrophotometer in 2 time points (1.0 and 
2.5 hours) after administration of 1 U and 2 U of insulin. Potency 
of AKR was calculated with 95% CI. Pharmacodynamic effect was 
based on glucose concentration measurement in rats with hypergly-
cemia induced by streptozotocin. The overall glycemic profile up to 
36 hours was evaluated after subcutaneous single dosing at range 
2.5 to 10.0 U/kg b.w. In the 28-day multiple dose study, AKR was 
administered twice a day at dose 5.0 U/kg b.w.
Results: Percentage of maximum Deoxy-D-glucose uptake in 3T3-
L1 cells was similar for AKR and human insulin, except the highest 
concentration in which the hook effect was observed. The absolute 
potency of a new analogue determined in rabbits was 23.94 U/mg, 
and the potency ratio of AKR versus the insulin standard was 0.90. 
The relative potency was 38.35 U/mL with confidence limit of 32.99–
44.42 U/mL. The experiment on rats confirmed with a statistical 
significance (P < 0.05) hypoglycemic activity of AKR in comparison 
of control group both after single and multiple doses. Characteristics 
for AKR profile was rather fast beginning of action (0.5-1.0 hour) 
with the maximal effect at 6 hours postdose and quite prolonged 
return to initial values. The glucose levels were stable during 4-week 
administration.
Conclusion: Bioactivity of the novel insulin analogue AKR, con-
nected with glucose metabolism was confirmed in both in vitro and in 
vivo conditions. AKR is a candidate for a hypoglycemic drug product 
in diabetes care.
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Introduction: Current acute myocardial infarction (AMI) guidelines 
recommend the use of platelet aggregation inhibitors, beta-blockers, 
angiotensin-converting enzyme inhibitors (ACEI), or angiotensin II 
receptor blockers (ARB) and statins for in-hospital and long-term 
treatment. The aim of the study was to evaluate the changes in the 
prescription of these drugs in Estonian hospitals in 2001 versus 2007 
and in 2007 versus 2011.
Patients (or Materials) and Methods: We performed a retrospective 
cross-sectional study including random samples of hospitalized AMI 
cases. Chi-square test and logistic regression were used to study the 
changes in the prescription of the drugs.
Results: Final analysis included 423 cases in 2001, 687 cases in 2007, 
and 740 cases in 2011. The prescription rates of most drugs recom-
mended for in-hospital and for out-patient use improved (Table). 
Compared with 2001, in 2007 and 2011, more patients were pre-
scribed drugs from all 5 drug (sub)groups during hospitalization 
(3.3% vs 18.5% vs 26.5%; P < 0.001) and for outpatient use (3.8% 
vs 22.2% vs 33.1%; P < 0.001). In multivariate analysis, < 75-year-
old patients and those hospitalized into a tertiary care hospital were 
more likely to be prescribed drugs from all 5 drug (sub)groups.
Conclusion: Prescription of recommended drugs for AMI patients 
increased continuously during last years in Estonia. Continuous edu-
cation programs and future studies should focus to differences of 
drug utilization in tertiary and nontertiary hospitals, also to different 
patient subgroups (ie, elderly).
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Introduction: There are potential conflicts between authorities and 
companies to fund new premium-priced drugs, especially where 
there are safety and/ or budget concerns. Dabigatran exemplifies 
these issues due to variable drug concentrations, no known antidote, 
dependence on renal elimination, and considerably more expensive 
than warfarin. The latter is a concern with the growing prevalence 
of atrial fibrillation (AF). There are also issues with potentially 
re-designing anticoagulant services. As a result, there is a need to 
review authority activities regarding dabigatran and use the findings 
to develop new models to better manage the entry of new drugs in 
the future.
Patients (or Materials) and Methods: Descriptive review and 
appraisal of educational and other activities regarding dabigatran 
pre- to postlaunch in a systematic manner among > 30 European 
countries and regions. The findings were used to develop a new model 
Table. Prescription rates of recommended drugs in Estonia.
Year 2001 Year 2007
P 2001 vs 
2007 Year 2011
P 2007 vs 
2011
During hospitalization n = 423 n = 687 n = 740
Aspirin 87.7 90.1 0.212 88.5 0.333
P2Y12 inhibitors 8.5 34.8 < 0.001 42.3 0.004
Beta-blockers 77.8 80.1 0.363 76.2 0.080
ACEI/ARB 53.7 68.3 < 0.001 63.5 0.059
Statins 16.1 48.5 < 0.001 58.0 < 0.001
Outpatient use n = 344 n = 514 n = 473
Aspirin 82.6 88.5 0.013 92.0 0.069
P2Y12 inhibitors 9.9 41.1 < 0.001 52.9 < 0.001
Beta-blockers 70.1 80.4 0.001 82.9 0.307
ACEI/ARB 52.6 73.7 < 0.001 75.9 0.434
Statins 23.5 57.6 < 0.001 72.3 < 0.001
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to optimize the managed entry of new drugs in the future through an 
iterative process. This includes guidance for all key groups on future 
activities to achieve this.
Results: There have been multiple demand-side activities among 
countries to manage the utilization of dabigatran. This included 
extensive prelaunch activities, risk-sharing arrangements, prescribing 
restrictions, and monitoring of prescribing postlaunch against agreed 
guidance. Clinical pharmacologists played a key role in a number 
of countries. Reimbursement was denied in some countries due to 
concerns with its budget impact and/or issues with excessive bleed-
ing. Development of a new model and future guidance was proposed 
to better manage the entry of new drugs in the future, centring on 
3 pillars of pre-, peri-, and postlaunch activities. This was accom-
panied by guidance to all key stakeholder groups, including health 
authorities, physicians, patients, and pharmaceutical companies on 
suggested activities pre- to postlaunch to reduce the likelihood of new 
drugs being withdrawn as well as enhance their chances of funding. 
This included guidance on key considerations that authorities should 
consider when evaluating risk-sharing arrangements or developing 
patient registries.
Conclusion: Models for introducing new drugs are essential to 
optimize their prescribing especially where there are concerns. As a 
result, promote high prescribing standards postlaunch. Without such 
models, new drugs may be withdrawn prematurely and/ or struggle 
for funding.
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Introduction: The sustained increase of cardiovascular disease in 
the developing world is a truly challenge. While > 80% of all CVD 
deaths occur in developing countries, the lack of longitudinal stud-
ies hinders the extrapolation of international recommendations for 
CVD prevention to a given country in the absence of risk predictors 
developed from local epidemiologic data. A risk estimation system 
has been developed by adapting the Framingham equations published 
in 1998 using local information to predict overall CHD risk in the 
Chilean population assuming a constant odds ratio for the risk fac-
tors between populations. The predictive power of the Chilean risk 
estimator has not been assessed. We explored the validity of predic-
tion by the Chilean risk equations against the CHD events observed 
in the Chilean population.
Patients (or Materials) and Methods: We performed a simula-
tion study to compare the predicted events in a Realistic Virtual 
Population (RVP) to the events observed in the Chilean population 
over 10 years. The RVP represents 10% of Chilean adults aged 35 to 
79 years with the CVD risk profiles reported by the National Health 
Survey of 2003. We derived the 10-year rates of CHD fatal and 
nonfatal from the individual risks by age and gender categories. We 
obtained the 10-year rates observed by extrapolating the latest annual 
incidence rates of fatal CHD and hospital discharges after nonfa-
tal CHD from national statistics using the life tables method. We 
performed predicted-observed comparisons for the Chilean-adapted 
Framingham equations, the Framingham equations developed by 
Anderson et al, and the SCORE equations estimates.
Results: The overall CHD events were overestimated by the Chilean 
risk equations in men and women < 55 years and underestimated 
in individuals of both genders older than 55 years. The calibration 
defaults were greater in women compared with men in all age catego-
ries. The overestimation of CHD with the Framingham model used as 
a reference was maximal in the second age category for both genders. 
The CHD fatal events were underestimated by SCORE in men and 
women at all ages although the age-related risk gradient was closer 
to the observed gradient compared with Framingham’s predictions.
Conclusion: The contribution of risk factors to CHD risk appears to 
be different in the Chilean population compared with the US popu-
lation. Overall, SCORE showed improved performance to predict 
Chilean CHD deaths.
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Introduction: Arterial hypertension represents a major cause of car-
diovascular morbidity and mortality in the city of Novi Sad, Serbia, 
with every fourth adult inhabitant suffering from it. The aim of this 
study was to analyze patterns of antihypertensives usage within 
different age groups of patients (30–40, 50–60, 70–80 years) and 
between genders.
Patients (or Materials) and Methods: The study was conducted in 
Novi Sad (estimated population 350,000) from September 2011 to 
February 2012. The data about antihypertensives issued on pre-
scription were collected from state-owned pharmacies in Novi Sad. 
Consumption was calculated using the ATC/DDD methodology, and 
results were expressed in DDD/1000 inhabitants/d.
Results: The total use of antihypertensives issued on prescription 
in Novi Sad was 282.6 DDD/1000 inhabitants/d. ACE inhibitors 
were the most frequently used antihypertensives in all age groups. 
Higher usage of beta-blockers in age group 30 to 40 years compared 
with other age groups was shown. Diuretics and calcium antagonists 
were more frequently prescribed to patients in age groups 50 to 60 
and 70 to 80. Most commonly prescribed antihypertensive drug in 
age group 30 to 40 was enalapril, in contrast to amlodipin, the most 
commonly prescribed antihypertensive in age groups 50 to 60 and 
70 to 80. The consumption of angiotensin receptor antagonists was 
low (< 3%) within all age groups.Women accounted for 59.9% of 
total consumption of antihypertensives. Only in age group of 30 to 
40 years, more antihypertensives were prescribed to men (62.9%) 
while in the age groups 50–60 and 70–80, the usage of antihyper-
tensives was significantly higher in women. Beta-blockers were more 
commonly used in women than in men, while for other groups of 
antihypertensives, no difference in usage was observed between male 
and female patients.
Conclusion: Widespread usage of ACE inhibitors, and low usage of 
other antihypertensives, especially diuretics, points to therapeutic 
irrationalities. The most cost-effective drugs – diuretics - accounted 
for only 4% of total consumption. High usage of more expensive 
antihypertensive agents presents a financial challenge for health care 
system.
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